The latest claim news of Guangyuyuan:
On April 10, 2024, Guangyuyuan Traditional Chinese Medicine Co., Ltd. issued the "Announcement on the Resignation of Directors and Presidents", which shows:
The board of directors of Guangyuyuan Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as the "Company") recently received a written resignation report from Director Zhang Bin and Director and President Mr. Miao Hui, Mr. Zhang Bin applied for resignation as a director of the Company due to personal reasons, and after the resignation, Mr. Zhang Bin no longer holds any position in the Company. Mr. Miao Hui applied for resignation as president, director and member of the remuneration and appraisal committee of the Company due to personal reasons, and after his resignation, Mr. Miao Hui no longer holds any position in the Company. In accordance with the relevant provisions of the Articles of Association, the resignation reports of the two of them shall take effect from the date of delivery to the Board of Directors of the Company. The resignation of the two members will not cause the number of members of the Board to fall below the statutory minimum, nor will it affect the normal operation of the Board and the normal development of business management.
Prior to this, on March 25, 2024, Guangyuyuan Traditional Chinese Medicine Co., Ltd. received the "Prior Notice of Administrative Punishment and Market Prohibition" issued by the Shanxi Supervision Bureau of the China Securities Regulatory Commission (Jin Zheng Jian Zhi Zi [2024] No. 02, hereinafter referred to as the "Notice").
After investigation, the facts of Guangyuyuan Co., Ltd.'s suspected violation of the law are as follows: 1. The disclosure of the "buyout sales" model in the annual report of Guangyuyuan Co., Ltd. from 2016 to 2021 is untrue, and the subsidiary Shanxi Guangyuyuan Chinese Pharmaceutical Co., Ltd. (hereinafter referred to as Shanxi Guangyuyuan) and some downstream commercial companies have an agreement that "the product is unsalable and close to the expiration date, and can be returned unconditionally" Accounting policy, recognition of sales revenue in advance, and incorrect treatment of sales expenses, inaccurate attribution period of some sales expenses or accounting treatment that does not comply with the provisions of the accounting standards for business enterprises.
2. The above situation has led to false records in the annual report from 2016 to 2022 and the semi-annual report of 2023.
The SFC decides:
1. Give a warning to Guangyuyuan shares and impose a fine of 8 million yuan;
2. Give Zhang Bin a warning and impose a fine of 5 million yuan;
3. Give Fu Shuhong a warning and impose a fine of 2.5 million yuan;
4. Zhang Zhengzhi was given a warning and fined 2.5 million yuan;
5. Give Wang Junbo a warning and impose a fine of 1 million yuan;
6. Yang Hongfei was given a warning and fined 800,000 yuan;
7. Give Li Zhong a warning and impose a fine of 800,000 yuan;
8. Give a warning to Zhao voters and impose a fine of 500,000 yuan.
and imposed a 10-year ban on Zhang Bin from the securities market. From the date of the announcement of the decision by the Bureau, during the prohibition period, in addition to continuing to serve as a director, supervisor or senior management of the original securities issuer, it is also prohibited to engage in securities business, securities service business or serve as a director, supervisor or senior manager of another securities issuer in any other institution.
According to the Securities Law and the Several Provisions of the Supreme People's Court on the Trial of Civil Compensation Cases Arising from False Statements in the Securities Market, listed companies shall be liable for civil compensation if their rights and interests are damaged due to illegal information disclosure and misrepresentation, and the injured investors have the right to claim compensation for losses.
The reference conditions for the claim are as follows:
Those who bought 600771 between March 21, 2017 and December 28, 2023, and sold or continued to hold them after December 29, 2023 (inclusive).
The above claim registration conditions only represent the views of Xie Baoping's lawyer team, and are not used as any securities investment decisions and trading suggestions, and are subject to the final determination of the court.
Basis for violations:
On December 28, 2023, Guangyuyuan received the "Notice of Case Filing" (No. 0172023009 Zheng Jian Case Filing) issued by the China Securities Regulatory Commission.
On March 25, 2024, Guangyuyuan Traditional Chinese Medicine Co., Ltd. received the "Prior Notice of Administrative Punishment and Market Prohibition" (Jin Zheng Jian Zhi Zi [2024] No. 02) issued by the Shanxi Supervision Bureau of the China Securities Regulatory Commission.